Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
Jefferies: MannKind's Consumer Ads For Afrezza May Increase Awareness
MannKind 'Facing Low Profitability And Delayed Profits' As Afrezza Ramp Fizzles, Goldman Says
JP Morgan Downgrades MannKind; Jefferies Also Comments
Shaunak Deepak Recent News
Analyst: MannKind Afrezza Estimates Are Being Changed 'Based On Physician Feedback'
Jefferies Expects Exciting 2015 For MannKind
Jefferies & Company Raises Incyte (INCY) Target Price To $19
Jefferies & Company Raises ViroPharma (VPHM) Price Target To $18
Jefferies & Company Maintains Auxilium Pharmaceuticals (AUXL) Buy Rating